X-Linked Severe Combined Immunodeficiency Clinical Trials

Find X-Linked Severe Combined Immunodeficiency Clinical Trials Near You

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

Who is this study for? Child to adult male patients with Severe Combined Immune Deficiency
What treatments are being studied? Autologous CD34-Positive VSV-G Pseudotyped CL20-4i-EF1a-hyc-OPT Vector Hematopoietic Stem Cell Infusion
Status: Recruiting
Location: See location...
Intervention Type: Biological, Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This Phase I/II clinical trial will study the safety and potential benefits of gene therapy for up to 35 people aged 2 to 50 with X-linked severe combined immunodeficiency (XSCID), a rare genetic condition that makes it difficult to fight infections. The study is for patients with XSCID who have serious immune system problems, including those who continue to experience serious immune complications after a previous stem cell transplant, and who do not have a suitably matched sibling donor. Treatment uses the patient s own blood-forming stem cells, which are collected from the bloodstream. In a laboratory, a specially designed delivery system called a lentiviral vector adds a working copy of the affected gene to these cells to help them produce functioning immune cells. Before receiving the modified cells, patients will receive a reduced dose of busulfan, a chemotherapy medicine that makes room in the bone marrow for the treated cells. The dose may be further adjusted according to the study protocol, including for patients with significant organ damage. Alemtuzumab (Campath) may also be given when clinically indicated, including to address certain immune problems involving donor T cells from a previous transplant. The modified stem cells will then be returned through a single infusion into a vein. Researchers will monitor side effects, how well the modified cells survive and produce immune cells, and whether patients develop stronger immune function and better health. The main assessment will occur two years after treatment, with follow-up visits continuing through year five. A separate long-term follow-up study will monitor patients through year 15 for lasting benefits and delayed side effects, including cancer. This treatment is experimental, and its benefits and risks are not yet fully known.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 2
Maximum Age: 50
Healthy Volunteers: f
View:

• A proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA

• No available HLA matched sibling donor as determined before enrollment (HLA typing will be performed prior to enrollment)

• Must be between 2 and 50 years of age and weigh 10 kg

• If previously transplanted, must be 18 months post-HSCT

• Expected survival of at least 120 days.

• Participants of reproductive potential must agree to consistently use highly effective contraception throughout study participation and for at least 2 years post-treatment. Acceptable forms of contraception are:

⁃ -For males: Condoms or other contraception with partner.

• Documented to be negative for HIV infection by genome PCR

• The patient must be judged by the primary evaluating physician to have a suitable family and social situation consistent with ability to comply with protocol procedures and the long-term follow-up requirements.

• Medical lab data (historical) of severe B cell dysfunction (low or absent IgG levels, failed immune response to vaccines); OR demonstrated requirement for intravenous gamma globulin (IVIG) (significant drop over 3 to 6 weeks between peak and trough IgG levels).

• Must be willing to have blood and tissue samples stored IN ADDITION, patients must satisfy the following Laboratory Criteria AND Clinical Criteria

‣ Laboratory Criteria: (\>=1 must be present)

‣ I. CD4+ lymphocytes: absolute number \<= 50% of the lower limit of normal (LLN)

‣ II. CD4+ CD45RA+ lymphocytes: absolute number \<= 50% of the LLN OR T-cell receptor excision circles (TRECs) \<= 5% of normal for age.

‣ III. Memory B Cells: absolute number \<= 50% of LLN

‣ IV. Serum IgM\<normal for age

‣ V. NK cells: absolute number \<= 50% of LLN

‣ VI. Lymphocyte proliferative response to each of 2 mitogens, phytohemagglutinin (PHA) and concanavalin A (ConA), is \<= 25% compared with a normal control.

‣ VII. Molecular spectratype analysis- absent or very oligoclonal (1-3 dominant peaks) in \>=6 of the 24 VBeta T-cell receptor families.

‣ Clinical Criteria: (\>=1 must be present):

‣ I. Infections (not including molluscum, warts or mucocutaneous candidiasis; see vii and viii below):

‣ Three significant new or chronic active infections during the 2 years preceding evaluation for enrollment, with each infection accounting for one criteria.

‣ Infections are defined as an objective sign of infection (fever \>38.3 degrees C \[101 degrees F\] or neutrophilia or pain/redness/swelling or radiologic/ultrasound imaging evidence or typical lesion or histology or new severe diarrhea or cough with sputum production). In addition to one or more of these signs/symptoms of possible infection, there also must be at least 1 of the following criteria as evidence of the attending physician's intent to treat a significant infection (a. and b.) or objective evidence for a specific pathogen causing the infection (c.)

⁃ Treatment (not prophylaxis) with systemic antibacterial, antifungal or antiviral antibiotics 14 days

⁃ OR

⁃ Hospitalization of any duration for infection

⁃ OR

⁃ Isolation of a bacteria, fungus, or virus from biopsy, skin lesion, blood, nasal washing, bronchoscopy, cerebrospinal fluid or stool likely to be an etiologic agent of infection

‣ II. Chronic pulmonary disease as defined by:

⁃ Bronchiectasis by x-ray computerized tomography

⁃ OR

⁃ Pulmonary function test (PFT) evidence for restrictive or obstructive disease that is 60% of Predicted for Age

⁃ OR

⁃ Pulse oximetry 94% in room air (if patient is too young to comply with performance of PFTs).

‣ III. Gastrointestinal enteropathy:

⁃ Diarrhea-watery stools 3 times per day (of at least 3 months duration that is not a result of infection as defined in criterion # i. above)

⁃ OR

⁃ Endoscopic evidence (gross and histologic) for enteropathy (endoscopy will only be performed if medically indicated)

⁃ OR

⁃ Other evidence of enteropathy or bacterial overgrowth syndrome: including malabsorption of fat-soluble vitamin(s), abnormal D-xylose absorption, abnormal hydrogen breath test, evidence of protein losing enteropathy (for example increasingly high or frequent dosing of intravenous gamma globulin supplement required to maintain blood IgG level).

‣ IV. Poor nutrition: Requires G-tube or intravenous feeding supplement to maintain weight or nutrition.

‣ V. Auto- or allo-immunity: Examples must include objective physical findings that include, but are not limited to any one of alopecia, severe rashes, uveitis, joint pain with redness or swelling or limitation of movement that is not a result of infection, lupus-like lesions, and granulomas (Does not include auto- or allo-immune enteropathy which is criterion iii). Where possible and appropriate, diagnosis will be supported by histopathology or other diagnostic modality.

‣ VI. Failure to grow in height: \<=3rd percentile for age

‣ VII. Skin molluscum contagiosum OR warts (this criterion is satisfied if molluscum consists of 10 lesions or there are two or more lesions at each of two or more widely separated anatomic sites; or there are 3 warts at different anatomic sites at the same time; or the patient has both molluscum and warts)

‣ VIII. Mucocutaneous candidiasis (chronic oral thrush or candida esophagitis or candida intertriginous infection or candida nail infections; must be culture positive to satisfy this criterion)

‣ IX. Hypogammaglobulinemia: requires regular IgG supplementation

‣ Criteria for eligibility for Campath (alemtuzumab):

‣ Evidence of organ disease attributable to T cell dysregulation, for example, elevated transaminases.

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Suk S De Ravin, M.D.
sderavin@mail.nih.gov
(301) 496-6772
Time Frame
Start Date: 2012-09-25
Estimated Completion Date: 2032-12-31
Participants
Target number of participants: 40
Treatments
Other: cohort a
First 8 Patients Treated
Other: cohort b
Patients 9 and Beyond
Sponsors
Leads: National Institute of Allergy and Infectious Diseases (NIAID)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials